Kestrel Therapeutics received IND clearance from the FDA for KST‑6051, an oral small‑molecule pan‑KRAS inhibitor targeting KRAS‑driven cancers, clearing the way for a first‑in‑human Phase I FALCON study expected to start by the end of the quarter. The approval positions Kestrel among a growing number of companies pursuing direct KRAS inhibition with oral modalities and expands clinical options for tumors driven by KRAS mutations.